How to Get Your Korean Sunscreen FDA-Cleared: The 2026 OTC Monograph Playbook for Indie Founders

By Liz Song, K-beauty sourcing consultant. Reviewed for accuracy by ALTA MEET's formulation consulting team.

Every US-bound Korean sunscreen sits on a different regulatory shelf than the rest of your line. Cleansers, serums, and creams clear US customs as cosmetics. Sunscreen clears as an over-the-counter drug. That reclassification trips up more indie K-beauty launches than any ingredient or MOQ decision.

This playbook walks through the FDA OTC monograph in plain founder language, tells you which UV filters your Korean ODM can and cannot use, and lays out the SPF testing and document trail you need before your first US shipment leaves Incheon.

Key Takeaways

• In the US, a sunscreen is a nonprescription drug under FDA's OTC monograph, not a cosmetic. Facility, testing, and labeling rules are stricter than for the rest of your K-beauty line.
• The list of UV filters FDA has recognized under the current OTC monograph is short. Popular Korean and European filters like MBBT, DHHB, and Bemotrizinol are not on it.
• SPF and broad-spectrum testing must follow FDA's methods, not just ISO 24443 or 24444, if you want a US-legal SPF claim on the front label.
• MOCRA still applies for the cosmetic side of your brand, but sunscreens carry an additional OTC drug facility registration, drug listing, and cGMP burden.
• Skipping any single document in the export packet is the fastest route to an FDA detention notice at the port.

Korean Sunscreens Are OTC Drugs in the US, Not Cosmetics

A sunscreen is a nonprescription drug in the US whenever the label makes an SPF, broad-spectrum, or UV protection claim. That reclassification pulls the product out of the ordinary cosmetic framework and into the FDA Center for Drug Evaluation and Research pathway, with facility, testing, and labeling obligations that most indie K-beauty founders never see on their moisturizer or cleanser.

In Korea, sunscreens are handled as functional cosmetics under MFDS review, which is why your Korean ODM can list an SPF number on a Korean label with a functional cosmetic notification (source: MFDS English portal, functional cosmetics category). The Korean pathway does not translate directly. The FDA classifies a Korean sunscreen as an OTC drug the moment it enters US commerce, even if the exact same tube ships freely across Asia.

The practical impact is that your Korean ODM has to satisfy US OTC drug cGMP under 21 CFR 210 and 211 for the sunscreen SKU, or you have to route the sunscreen through a US contract manufacturer for the finishing step. Facility registration and drug listing sit with FDA's Structured Product Labeling system, separately from cosmetic listings under MOCRA (FDA drug establishment registration).

What UV Filters Are Actually Allowed on the FDA Monograph in 2026?

The FDA OTC sunscreen monograph currently recognizes 16 UV filters as Generally Recognized as Safe and Effective. The list includes zinc oxide, titanium dioxide, avobenzone, octinoxate, octisalate, homosalate, octocrylene, oxybenzone, ensulizole, and a handful of others (source: FDA sunscreen consumer overview and 21 CFR 352).

The filters your Korean ODM most often reaches for are not on that US list. Bemotrizinol (Tinosorb S), Bisoctrizole (Tinosorb M, also called MBBT), Diethylamino Hydroxybenzoyl Hexyl Benzoate (DHHB, also called Uvinul A Plus), and Iscotrizinol (Uvasorb HEB) are approved for Korean and European use but not on the current US OTC monograph. FDA has been reviewing several of these under the Sunscreen Innovation Act framework for years without issuing a new final order (FDA Sunscreen Innovation Act).

For a US-facing SKU, your ODM must reformulate to a US monograph filter system. That usually means a mineral base (zinc oxide with or without titanium dioxide) or an older chemical system (avobenzone stabilized with octocrylene). Elegance suffers relative to the Bemotrizinol-based formulas Korean consumers know, and that is the single biggest formulation trade-off in this category.

The Six Document Sets Your Korean ODM Must Produce Before Ship-Out

Before your first US-bound pallet leaves Incheon, your ODM's regulatory affairs team should hand you six document packets. Each maps to a specific FDA gate at import.

First, an FDA drug establishment registration (also called Establishment Registration under 21 CFR 207) confirming the Korean facility is on file with FDA as a drug manufacturer. Second, a Structured Product Labeling drug listing for the specific sunscreen SKU with its NDC number. Third, a cGMP audit summary against 21 CFR 210 and 211, including batch records and stability protocols. Fourth, a full SPF and broad-spectrum test report from an FDA-recognized method. Fifth, a monograph compliance statement confirming that every active ingredient sits within the concentration limits set in 21 CFR 352. Sixth, a Drug Facts label layout that follows FDA's required format, panel order, and font sizing.

Get all six confirmed in writing before your first purchase order signs. Retrofitting after the batch is filled is a slow, expensive path.

How Do You Test SPF for a US-Facing Sunscreen Correctly?

SPF testing for a US label claim must follow FDA's in vivo human testing procedure detailed in 21 CFR 201.327, which references FDA's own test method rather than ISO 24444 directly. Broad-spectrum protection requires an in vitro critical wavelength test with a minimum critical wavelength of 370 nm (21 CFR 201.327).

Most Korean CROs test to ISO 24444 for in vivo SPF and ISO 24443 for in vitro UVA, which is what MFDS accepts. The results are scientifically sound, but the specific procedural details, panel size requirements, and reporting format do not always satisfy an FDA reviewer or a State Attorney General challenging your SPF claim. The safest path is a US or FDA-compliant CRO running the FDA method in parallel, or a Korean CRO that publicly documents FDA-method compliance.

Water resistance claims (Water Resistant 40 minutes or Water Resistant 80 minutes) require additional immersion testing under the same FDA framework. There is no such thing as "waterproof" or "sweatproof" on a US label. FDA prohibits those terms outright.

I'm Liz, and I run ALTA MEET from Manhattan, NYC, working with Korean sunscreen ODMs weekly. The single question that separates a launch that ships from one that gets detained is whether the founder understood, before signing, that a Korean sunscreen is a US drug. If you want a 15-minute gut-check on your specific SKU, allowed filters, and testing plan, email me at liz@altameet.com or book a slot on my calendar.

Three Common Founder Mistakes That Trigger FDA Detention

The first mistake is assuming that a strong SPF number on a Korean label transfers to a US label. It does not. If the active ingredients include Bemotrizinol, DHHB, or MBBT, the product cannot be sold as an OTC sunscreen in the US regardless of how well it tests in Seoul. It has to be reformulated on US monograph filters or filed as a New Drug Application, which is not a viable indie path.

The second mistake is treating MOCRA registration as sufficient. MOCRA covers the cosmetic side of your brand and is required for every non-sunscreen SKU (see our FDA and Korean skincare import guide for the cosmetic pathway). Sunscreens need MOCRA registration for the brand plus separate FDA drug establishment registration for the manufacturing site plus SPL drug listing for the SKU. Three parallel filings, not one.

The third mistake is skipping the Drug Facts label. Sunscreens require a Drug Facts panel with a specific order (Active Ingredient, Purpose, Uses, Warnings, Directions, Inactive Ingredients, Other Information). A pretty K-beauty back label with only INCI and a Made in Korea line is misbranding and triggers customs refusal.

What Is the Actual Compliance Timeline for a Korean Sunscreen Launch?

A US-compliant Korean sunscreen launch typically takes six to nine months from first RFQ to first pallet at your US warehouse, assuming reformulation to US filters. The critical path is the reformulation and stability testing loop, not the customs filings.

Weeks 1 to 4 cover ODM shortlist and RFQ with a US-only spec (US monograph filters, US target SPF, US Drug Facts layout). Weeks 5 to 12 cover benchtop reformulation, initial stability, and consumer texture testing. Weeks 13 to 20 cover pilot batch, formal 12-week accelerated stability, SPF and broad-spectrum testing, and packaging engineering. Weeks 21 to 28 cover FDA drug establishment registration for the manufacturing site (if not already registered), SPL drug listing, MOCRA registration, first commercial batch, and customs pre-clearance.

If your Korean ODM already runs a US-registered sunscreen line for another brand, the whole timeline compresses by two to three months. That is one of the sharpest questions to ask on the first RFQ call. For a broader look at the indie K-beauty launch sequence beyond sunscreen, our complete guide to starting a K-beauty skincare brand lays out the parallel workstreams for the rest of your line.

If you are evaluating a Korean sunscreen SKU for your US line, email Liz at liz@altameet.com, reach the ALTA MEET partnerships team at partnerships@altameet.com, or book a 15-minute gut-check on Liz's calendar. Also see our how to sell Korean cosmetics in the US founder playbook for the retail and DTC channel side of a US launch.